Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 23, 2020
Daily News
April 23, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
- World’s 1st Topical JAK Inhibitor to Hit Shelves on June 24: JT/Torii
April 23, 2020
- Nichi-Iko Recall Hits Towa’s Teprenone Supply
April 23, 2020
- In a First, Chuikyo to Be Streamed Live amid COVID-19 Outbreak
April 23, 2020
- Pfizer Japan Further Extends Work-from-Home through May-End
April 23, 2020
- Remicade Biosimilars OK’ed for Behcet’s-Associated Uveitis
April 23, 2020
- Ube Industries to Start Avigan Intermediate Supplies from July
April 23, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
- JCR to Develop 2 Mucopolysaccharidosis Drugs Using BBB-Penetrating Technology
April 23, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…